Introduction {#s1}
============

SLE is a chronic autoimmune condition that disproportionately strikes women and ethnic minorities.[@R1] Incidence and prevalence are 10-fold to 15-fold higher in women compared with men and threefold higher in African--American women compared with their white counterparts.[@R2] Mortality is threefold to fourfold higher in SLE than the general population, and African--Americans are more likely to experience poor outcomes than whites.[@R6] Proper medical care and patient engagement in self-management play a major role in SLE outcomes.[@R9] Yet people of African--American ethnicity and low socioeconomic status face formidable barriers to accessing healthcare and self-management education.[@R9]

Participation of high-risk SLE populations in intervention trials is a public health priority for reducing health disparities.[@R18] However, African--Americans have been historically under-represented and engaging them in research is challenging. Moreover, while clinical trial representation of other racial minorities with SLE has increased over time, the participation of African--Americans has decreased from 2006 to 2011.[@R19]

Not only do African--American women represent a health disparities population disproportionately impacted by SLE, but this group is also at high risk for poor outcomes. Nearly 90% of nationwide hospitalised patients with SLE are women, and mortality in this group is the highest.[@R20] Under-representation of African--American women limits the generalisability of findings, the provision of effective treatment and the development of tailored behavioural interventions aimed at improving self-care.[@R22] Given the complexity of health problems associated with SLE, education is critical to promoting positive self-management practices.[@R23] Although promising self-management interventions specific to SLE are currently being examined,[@R26] we still lack widely available evidence-based programmes. Moreover, we are unaware of behavioural trial participation barriers of African--Americans women with SLE.

The Chronic Disease Self-Management Program (CDSMP), a community-based, evidence-based programme designed to enhance self-management skills in people with chronic conditions, may benefit African--American women with SLE.[@R29] Since 2003, the US Administration on Aging has promoted the development of infrastructure to deliver the programme across multiple states.[@R30] Although it is difficult to determine the number of CDSMP sites or programmes at any time, the Evidence-Based Leadership Council programme locator indicates that there is at least one and usually multiple sites offering the CDSMP in every US state.[@R31] Although not SLE-specific, the CDSMP core curriculum addresses many of the self-care challenges faced by women with SLE. Moreover, because its widespread availability, the CDSMP can be leveraged as an accessible option for targeting African--American women with SLE in the community.

The CDSMP has demonstrated to be effective in improving self-management behaviours and outcomes in African--American populations with arthritis and multiple comorbidities.[@R25] Building on a pilot study that reported promising benefits of the CDSMP among low-income African--American women with lupus,[@R32] we are now conducting a 5-year behavioural trial called the Women Empowered to Live with Lupus (WELL) study. The WELL study intends to fill a need for an accessible intervention that can potentially improve outcomes in African--American women with SLE. This report provides an overview of the WELL study design, followed by the recruitment and data collection methods, and the assessment of barriers and strategies implemented to overcome recruitment and retention barriers among African--American women participating in the CDSMP.

Methods {#s2}
=======

WELL study overview {#s2-1}
-------------------

### Sample {#s2-1-1}

We leveraged the population-based Georgians Organized Against Lupus (GOAL) cohort to conduct the WELL study. Primarily derived from one of the five National Lupus Patient Registries supported by the Centers for Disease Control and Prevention,[@R2] GOAL is a cohort with a large number of African--American patients with SLE from Atlanta, Georgia.[@R33] Participants include patients from a broad socioeconomic spectrum served at community practices, and the Emory and Grady Health Systems. By 30 November 2019, GOAL encompassed 1234 adults with a validated diagnosis of SLE.

### The intervention {#s2-1-2}

The CDSMP is a globally disseminated, evidence-based programme designed to enhance self-efficacy to manage chronic diseases (eg, heart disease, arthritis).[@R29] Conducted among small groups (10--16 participants) in the community by two certified peers, the CDSMP workshop consists of 6 weekly classes, each lasting 2.5 hours. Lay leaders are trained and certified according to the Self-Management Resource Center (previously the Stanford Patient Education Center) protocol. Classes are highly participative through weekly action plans, behaviour modelling, vicarious learning, problem solving and peer support. The CDSMP addresses self-management challenges that are universal across chronic conditions, including pain and fatigue, symptom and medication management, communication with family and professionals, managing emotions, exercise, and healthy eating. Participants must attend ≥4 classes to be a 'CDSMP completer'.

### Study design {#s2-1-3}

We implemented a two-group longitudinal cohort study nested within GOAL to examine changes in outcomes between participants enrolled in the CDSMP (hereafter called the WELL cohort) and the remaining GOAL participants not exposed to the intervention (the Usual Care cohort). Given the long-standing (\>8 years) relationship between GOAL participants and the research staff, this is a cost-effective approach to recruit and examine an adequate sample size and obtain a representative sample of African--American women with SLE from metropolitan Atlanta ([figure 1](#F1){ref-type="fig"}).

![Overview of the study design. AA, African--American; CDSMP, Chronic Disease Self-Management Program; GOAL, Georgians Organized Against Lupus; WELL, Women Empowered to Live with Lupus study.](lupus-2020-000391f01){#F1}

CDSMP recruitment, data collection and barriers assessment {#s2-2}
----------------------------------------------------------

### Research coordination team {#s2-2-1}

Three black/African--American female research coordinators (RC) with experience in research among ethnic minorities with SLE were responsible for recruitment and data collection, and participated in barriers assessment and resolution.

### Recruitment {#s2-2-2}

We selected a random sample from GOAL using the following inclusion criteria: (1) self-reported African--American race; (2) female sex; (3) meeting ≥4 American College of Rheumatology (ACR) criteria for the classification of SLE or meeting 3 ACR criteria and having a documented diagnosis of SLE by a board-certified rheumatologist; and (4) residence in metropolitan Atlanta, where community-based CDSMP workshops are provided. Women selected received a phone call by the RC explaining the study. Among those interested, the RC discussed the commitment needed to ensure study integrity and assessed exclusion criteria. Exclusion criteria were participation in the CDSMP in the past 5 years and cognitive impairment, which was screened via telephone using the Six-Item Screener tool.[@R39] Eligible women were mailed a recruitment packet, which included a flyer, the consent, schedule and location of upcoming CDSMP workshops, and staff contact information. A form to enter participants' preferred contact method, workshop time availability and transportation preferences was also included. The Emory Institutional Review Board approved the informed consent to be conducted via online, telephone or in person. Recruitment was finalised once a consented participant was registered in a specific CDSMP workshop.

The Usual Care cohort encompassed GOAL participants who at baseline met the same inclusion criteria as WELL participants, but were not exposed to the CDSMP (shaded square in [figure 1](#F1){ref-type="fig"}). Using data from our pilot study, we calculated that a sample of 150 WELL and 242 Usual Care participants would provide 80% power to demonstrate a clinically meaningful improvement (2.5 points change) in patient-reported outcomes after the CDSMP.[@R32]

### CDSMP registration {#s2-2-3}

Most CDSMP workshops delivered in Atlanta are coordinated by the Atlanta Regional Commission (ARC), which is the regional planning and intergovernmental agency that provides community services to residents of metropolitan Atlanta and is licensed to deliver the CDSMP. Workshops schedule and location were coordinated between the RC and the ARC to facilitate the registration of WELL participants into workshops at convenient locations and schedules. The importance of attending all CDSMP classes was emphasised during recruitment. Workshop registration was finalised by the RC via telephone after a participant provided her availability through the paper form or a phone contact. Options for transportation to the CDSMP classes included a \$10 subway or gas card, or a round-trip ride (Uber/Lyft). Weekly phone calls were conducted among CDSMP participants to assess classes attendance and provide transportation compensation or the upcoming ride service.

### Measures and data collection {#s2-2-4}

Measures were selected to minimise participants' burden ([table 1](#T1){ref-type="table"}). We deliver one preintervention and three postintervention (6-month, 12-month, 18-month) surveys in the WELL cohort and four surveys separated by 6 months in the Usual Care group. We have been successfully using the Dillman's Total Design Method with minor modifications to obtain high survey response rates.[@R40] It is based on the social exchange principle and operational aspects to minimise costs and maximise rewards for responding, and establish trust that rewards will be delivered. Participants have multiple options for completing the surveys, and the average duration for responding the WELL survey is 40 min. Reminders are conducted through emails, text messages or phone calls. WELL participants receive gift cards of \$35, \$40, \$45 and \$50 for completing the baseline, 6-month, 12-month and 18-month assessments, respectively.

###### 

Summary of self-reported measures

  -------------------------------------------------------------------------------------------------------------------------
  Category                                                       Construct                                  Measure
  -------------------------------------------------------------- ------------------------------------------ ---------------
  Demographics                                                   Age                                        Ad hoc

  Disease duration                                               Ad hoc                                     

  Education                                                      Ad hoc                                     

  Work status                                                    Ad hoc                                     

  Health-related quality of life                                 PROMIS global health-physical              PROMIS SF10

  PROMIS global health-mental                                    PROMIS SF10                                

  PROMIS depression                                              PROMIS SF8a                                

  PROMIS physical function                                       PROMIS SF10b                               

  PROMIS pain interference                                       PROMIS SF8a                                

  PROMIS fatigue                                                 PROMIS SF8a                                

  PROMIS sleep disturbance                                       PROMIS SF8a                                

  PROMIS anxiety                                                 PROMIS SF8a                                

  PROMIS anger                                                   PROMIS SF5a                                

  PROMIS ability to participate in social roles and activities   PROMIS SF8a                                

  Self-management\                                               PROMIS self-efficacy to manage medicines   PROMIS SF8a
  beliefs and behaviours                                                                                    

  PROMIS self-efficacy to manage symptoms                        PROMIS SF4a                                

  Communication with physicians                                  3-item Stanford Scale                      

  Patient Activation Measure                                     PAM                                        

  Psychosocial factors                                           Perceived stress                           Cohen Scale 4

  PROMIS emotional support                                       PROMIS SF4a                                

  PROMIS informational support                                   PROMIS SF4a                                

  PROMIS instrumental support                                    PROMIS SF4a                                

  PROMIS social isolation                                        PROMIS SF6a                                

  Everyday discrimination                                        Williams Everyday Discrimination Scale     

  Disease severity                                               Disease activity                           SLAQ

  Organ damage                                                   SA-BILD                                    
  -------------------------------------------------------------------------------------------------------------------------

PAM, Patient Activation Measure, used under Insignia Health licence; PROMIS SF, Patient-Reported Outcome Measurement Information System Short Form; SA-BILD, Self-Administered Brief Index of Lupus Damage; SLAQ, Systemic Lupus Activity Questionnaire.

### Project management procedures {#s2-2-5}

Performance standards were established by defining specific recruitment, retention and data collection targets. We implemented strategies that have been shown to be successful over the years, including training staff in outreach, recruitment and retention of minority individuals, building trustful interactions, frequent contact with participants, and face-to-face enrolment when possible. A Health Insurance Portability and Accountability Act (HIPAA)-compliant project management system was built to track WELL operational tasks, allowing us to run searches and progress reports of subjects reached, refused, unable to participate, interested, screened, consented and registered into a CDSMP workshop. The system was also configured to report class attendance and completion of postintervention data collection time points, and take text notes.

### Assessment of recruitment and retention barriers {#s2-2-6}

The RC conducted phone calls among consented participants to coordinate CDSMP registration and assess CDSMP classes attendance. Individualised notes were taken at each telephone encounter to capture participant barriers related to the different phases of the study, including reasons for missing classes. Monthly meetings were conducted among all research members to discuss progress, barriers and possible solutions. Meetings were also conducted with ARC partners to discuss barriers related to CDSMP workshop scheduling.

Results {#s3}
=======

Recruitment of the WELL cohort {#s3-1}
------------------------------

Recruitment from a GOAL sample of 723 African--American women with SLE began in January 2017 ([figure 2](#F2){ref-type="fig"}). Twenty-two participants were excluded because they reported exposure to an inperson self-management workshop in the past 5 years. By April 2019, 354 randomly selected women were reached and 268 (75.7%) who were interested in the CDSMP were further screened for cognitive impairment. We excluded two who tested positive and confirmed that none of the screened participants attended the intervention within the last 5 years. Of 266 eligible women, 228 (85.7%) consented to participate. Of the 228, 203 (89.0%) registered into a CDSMP workshop and 168 of 203 (82.8%) attended at least one CDSMP class by May 2019, comprising the WELL cohort. The Usual Care cohort encompassed 531 GOAL participants not exposed to the intervention. [Table 2](#T2){ref-type="table"} describes the baseline characteristics of participants.

![Recruitment of the WELL and Usual Care cohorts. CDSMP, Chronic Disease Self-management Program; GOAL, Georgians Organized Against Lupus; SM, self-management; WELL, Women Empowered to Live with Lupus study; WS, workshop.](lupus-2020-000391f02){#F2}

###### 

Baseline characteristics of WELL and Usual Care participants

  -------------------------------------------------------------------------------------------------------------------------------------
  Category                                                       Measure                                    Usual Care\   WELL\
                                                                                                            (n=531)       (n=168)
  -------------------------------------------------------------- ------------------------------------------ ------------- -------------
  Demographics                                                   Age (years)                                47.3 (14.0)   49.8 (12.3)

  Disease duration (years)                                       15.4 (10.5)                                16.4 (9.9)    

  Education (years)                                              14.1 (2.8)                                 14.3 (2.9)    

  Work status, n (%)                                                                                                      

  Working full time                                              147 (27.9)                                 28 (16.8)     

   Working part-time                                             63 (12.0)                                  11 (6.6)      

   Retired                                                       68 (12.9)                                  22 (13.2)     

   Home maker                                                    29 (5.5)                                   2 (1.2)       

   Student                                                       17 (3.2)                                   4 (2.4)       

   Unemployed or disabled                                        202 (38.4)                                 100 (59.9)    

  Health-related quality of life                                 PROMIS global health-physical              40.6 (8.8)    38.3 (7.5)

  PROMIS global health-mental                                    43.5 (9.2)                                 41.4 (9.0)    

  PROMIS depression                                              51.1 (10.9)                                53.5 (9.2)    

  PROMIS physical function                                       40.6 (10.0)                                38.4 (7.6)    

  PROMIS pain interference                                       57.7 (10.1)                                59.0 (9.2)    

  PROMIS fatigue                                                 57.5 (11.2)                                58.6 (10.6)   

  PROMIS sleep disturbance                                       56.7 (10.7)                                57.3 (10.8)   

  PROMIS anxiety                                                 51.9 (11.4)                                53.9 (10.5)   

  PROMIS anger                                                   51.2 (12.5)                                53.0 (11.4)   

  PROMIS ability to participate in social roles and activities   47.5 (10.1)                                45.3 (8.3)    

  Self-management\                                               PROMIS self-efficacy to manage medicines   46.2 (9.2)    46.0 (9.0)
  beliefs and behaviours                                                                                                  

  PROMIS self-efficacy to manage symptoms                        48.3 (8.7)                                 47.1 (7.8)    

  Communication with physicians\*                                2.9 (1.1)                                  3.1 (1.1)     

  Patient Activation Measure (PAM), n (%)                                                                                 

   Level 1 (disengaged and overwhelmed)                          39 (7.5)                                   12 (7.3)      

   Level 2 (becoming aware, still struggling)                    123 (23.5)                                 24 (14.5)     

   Level 3 (taking action)                                       264 (50.5)                                 90 (54.5)     

   Level 4 (maintain behaviours/push further)                    97 (18.5)                                  39 (23.6)     

  Psychosocial factors                                           Perceived stress†                          6.3 (3.2)     6.2 (3.2)

  PROMIS emotional support                                       51.3 (9.3)                                 51.4 (9.2)    

  PROMIS informational support                                   53.6 (10.7)                                52.4 (9.9)    

  PROMIS instrumental support                                    53.1 (9.3)                                 51.4 (9.2)    

  PROMIS social isolation                                        47.3 (10.9)                                49.9 (10.9)   

  Everyday discrimination‡                                       1.6 (0.6)                                  1.7 (0.6)     

  Disease severity                                               Disease activity (SLAQ score)§             14.4 (8.7)    16.9 (8.6)

  Organ damage score level¶, n (%)                                                                                        

   No damage (SA-BILD score=0)                                   112 (21.3)                                 29 (17.3)     

   Mild damage (SA-BILD score=1--2)                              210 (39.8)                                 58 (34.5)     

   Severe damage (SA-BILD score ≥3)                              205 (38.9)                                 81 (48.2)     
  -------------------------------------------------------------------------------------------------------------------------------------

Statistic values are displayed as mean (SD) unless otherwise specified.

PROMIS measures are reported using a T-score metric in which 50 is the mean and 10 is the SD of a reference population, with higher scores indicating more of the domain being measured.

\*Scores range from 0 to 5, with higher scores indicating better communication.

†Scores range from 0 to 16, with higher scores indicating higher perceived stress.

‡Scores range from 1 to 4, with higher scores indicating higher perceptions of discrimination.

§Scores range from 0 to 47, with higher scores indicating higher disease activity.

¶Scores range from 0 to 30, with higher scores indicating higher lupus damage.

PROMIS, Patient-Reported Outcome Measurement Information System Measure; SA-BILD, Self-Administered Brief Index of Lupus Damage; SLAQ, Systemic Lupus Activity Questionnaire; WELL, Women Empowered to Live with Lupus study.

Expected and achieved recruitment {#s3-2}
---------------------------------

We projected to consent an average of 10 WELL participants/month to achieve a sample of 150 participants in 2 years (blue line in [figure 3](#F3){ref-type="fig"}). We also expected that 150 WELL participants would attend the CDSMP by 30 May 2019. No substantial barriers were identified to recruit GOAL participants into the WELL cohort ([figure 3](#F3){ref-type="fig"}); however, early in the study we learnt that WELL participants faced barriers to registering for and/or attending the CDSMP classes (see the following section). We revisited our approach by consenting a higher number of participants than the actual sample size needed in the intervention arm, allowing to have a sufficient pool of participants to take part into upcoming CDSMP workshops. Monthly recruitment progress of the WELL cohort is depicted in [figure 3](#F3){ref-type="fig"}.

![Monthly recruitment, CDSMP registration and CDSMP attendance. CDSMP, Chronic Disease Self-management Program; WELL, Women Empowered to Live with Lupus.](lupus-2020-000391f03){#F3}

Participation in the CDSMP and retention in the study {#s3-3}
-----------------------------------------------------

We faced challenges in accommodating WELL participants into existing CDSMP workshops. The most significant ones were (1) workshop cancellation due to low enrolment; (2) frequent no-shows or last-minute cancellations to attend a specific workshop; and (3) low workshop completion rate ([table 3](#T3){ref-type="table"}). We also identified a relatively low rate of 6-month survey responses (80.9% respondents within the first year). We describe the main challenges and the strategies implemented to overcome these challenges.

###### 

Summary of recruitment and retention of African--American women with SLE into the CDSMP: challenges, barriers, strategies and outcomes

  Challenge                                                                             Identified barrier                                                                                   Implemented strategy                                                                                                                                                                                                                                                                                                                                                                                                                                                      Outcome
  ------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Low registration into a CDSMP workshop.                                               CDSMP locations and scheduled not matching participants' needs.                                      Collaborative Emory-ARC efforts to coordinate CDSMP workshops that would meet study participants' needs.Support ARC community recruitment efforts.Increased the number of CDSMP workshops at convenient locations and schedules.CDSMP at libraries, health centres, churches, Grady and Emory facilities.CDSMP delivered on Saturdays.Increased the number of study participants registered per workshop (to prevent need to cancel workshops due to low registration).   42 CDSMP WS scheduled in 2 years.28 in community centres.14 in Grady and Emory facilities.14 CDSMP scheduled on Saturdays.Of 228 participants consented, 203 (89%) registered into a CDSMP.
  Participant no-shows or cancellation, after being registered into a CDSMP workshop.   Competing health and life-related demands.Unclear understanding of the CDSMP scope and objectives.   CDSMP demonstration (1-hour 'Session Zero').Reinvited to register for a different CDSMP workshop.CDSMP workshops on Saturdays.Provided information about the CDSMP at multiple points of the recruitment process.Culturally relevant recruitment material including a short informative/testimonial video with messages highlighting alignment of lupus patients' self-management needs with the intervention goals and benefits.                                         6 'Sessions Zero'; 28 attendees.Of 203 participants registered into a CDSMP, 168 (82.8%) attended ≥1 class.Attendance increased from 45 participants in the first half of the recruitment period to 123 participants in the second half.64 of 168 (38%) attended a Saturday-delivered CDSMP workshop.
  Low CDSMP completion rate (less than four classes attendance).                        Health and life-related demands.Variable transportation needs.Forgetfulness.                         Option to attend future CDSMP workshops.Flexible transportation options across the 6-week CDSMP.Weekly reminder via phone call/text message.Non-monetary incentive at class 3.                                                                                                                                                                                                                                                                                            The completion rate increased from 64.7% in the first 6 months since the intervention started to 80.0% in the second 6 months.The cumulative completion rate was 75.0% for the 2-year study period.
  Low rate of 6-month survey response.                                                  Competing demands.Forgetfulness.                                                                     Frequent, personalised contact by study staff.Survey reminders.Implemented a ±3-month window to complete the survey.Flexible survey delivery.Monetary and non-monetary incentives.                                                                                                                                                                                                                                                                                        The 6-month response rate was 80.9% for year 1 CDSMP participants and 98.9% for year 2 CDSMP participants.By 30 September 2019, the overall 6-month response rate was 92.3%.

ARC, Atlanta Regional Commission, an Atlanta-based organisation that owns the CDSMP licence; CDSMP, Chronic Disease Self-Management Program; WS, workshop.

### CDSMP registration {#s3-3-1}

We encountered difficulties matching participants' preferences with available CDSMP locations and schedules, causing a relatively low rate of CDSMP registration in relation to the number of participants consented. We implemented several strategies aiming at increasing the number of workshops that would meet the needs of our participants. First, the research staff provided support to the ARC with the coordination and delivery of CDSMP workshops. We constantly assessed the most convenient locations and schedules among WELL participants and informed the ARC coordinator about participants' preferences. Second, in addition to community centres nearby study participants' residency, workshops were delivered at facilities located at Grady and Emory campuses, which were found to be very convenient and familiar to many participants. Of the 42 CDSMP workshops delivered in a 2-year period, 28 (66.7%) took place in libraries, community health centres and churches, and the remaining 14 (33.3%) in Grady and Emory facilities. Additional workshops were delivered in the afternoons, and nine (7.1%) were scheduled on Saturdays. We also increased the number of WELL participants registered into each workshop to avoid CDSMP cancellations due to insufficient participants. As a result, among 228 women consented, 203 (89%) registered into a CDSMP. The cumulative proportion of participants registered into the CDSMP in relation to those consented increased from 43.4% by the 12th month to 89.0% by the end of the intervention period. As shown in [figure 3](#F3){ref-type="fig"}, a peak in CDSMP registration and attendance occurred between the 23rd month and the end of the intervention phase, which coincided with the delivery of seven workshops at Emory and Grady facilities, three of which were scheduled on Saturdays ([figure 3](#F3){ref-type="fig"}). Because CDSMP registration not only targeted recently consented participants, but also those who had been waiting to be accommodated, the total number of participants recruited into the CDSMP was 168 (black line in [figure 3](#F3){ref-type="fig"}), slightly surpassing the initial estimate of 150 (blue line in [figure 3](#F3){ref-type="fig"}). Eighty-two participants attended a workshop with other members of the community and the remaining 86 attended workshops exclusively with other participants with SLE.

### Participant cancellation or no-shows after being registered into a CDSMP workshop {#s3-3-2}

Additional challenges were last-minute cancellations to attend a specific CDSMP workshop or no-shows without notice. Two major barriers were recognised in relation to these challenges: (1) competing demands (eg, health issues, job schedule changes, childcare needs) and (2) lack of a clear understanding of the purposes and scope of the intervention. To reduce these barriers, we increased the number of workshops delivered on Saturdays and offered opportunities to register in an upcoming workshop to those participants who were still interested in the CDSMP. Additionally, we increased our efforts to better inform participants about the scope, commitment and goals of the CDSMP at multiple points during the recruitment processes. We used feedback from CDSMP completers and secondary data from a qualitative substudy to produce additional recruitment materials, including a short video that provided culturally relevant information about the intervention and a CDSMP participant's testimony.[@R11] Messages from those materials served to align the goals of the intervention with the self-management needs of our population. Additionally, we offered a standardised 1-hour information session prior to class 1, known as 'Session Zero', to nearly 200 participants who had not registered into the CDSMP.[@R42] Among 56 participants interested, 28 were able to attend, 11 were unavailable and 17 missed the session. This activity served to demonstrate the interactive nature of the workshop, encouraging enrolment at the end of the session. CDSMP attendance increased from 45 to 123 participants in the first and second half of the recruitment period, respectively.

### CDSMP completion rate {#s3-3-3}

In the first 6 months of the intervention phase, 11 of 17 (64.7%) participants completed four or more CDSMP classes, a rate substantially lower than the 75% reported nationwide.[@R42] The weekly phone calls conducted by the RC provided insightful feedback about attendance barriers. Unexpected demands from the underlying disease (eg, lupus flares, hospitalisations, medical appointments) or personal issues (eg, childcare needs, job demands) were identified as major barriers. To overcome these challenges, non-completers were given the opportunity to start another CDSMP workshop if they were motivated to do so. Additional barriers among non-completers included variable transportation needs over the 6-week CDSMP duration and forgetfulness about the next-week class. To address these, each participant was offered flexible weekly transportation options and received reminder messages the day before the upcoming class. To maintain engagement, a non-monetary token (WELL study bag and greeting card) was mailed to those who completed the third class. As a result, the CDSMP completion rate increased from 64.7% to 80.0% in the first and second 6 months of the intervention phase. The overall completion rate reached 75.0%. A slightly higher completion rate was observed for workshops delivered on Saturdays (76.6%) compared with weekdays (74.0%).

WELL cohort 6-month retention {#s3-4}
-----------------------------

Our project management system allows RC to track survey delivery and completion dates and take centralised notes across studies at each participant's encounter. These notes facilitated a personalised approach to address participant barriers and preferences to effectively provide data. Evaluation of postintervention data collection rendered an 80.9% rate of 6-month responses within the survey schedule in the first year. Major barriers were competing demands (eg, health and personal life events, participation in other studies) and forgetfulness. To increase retention, we applied a ±3-month window to each time point of data collection and made more frequent contact with participants to send reminders. Moreover, participants seen at our outpatient lupus clinic were offered the opportunity to complete any outstanding survey in a private room. We continued implementing successful retention strategies, such as flexible survey delivery modes (email, mail or by phone) and both monetary and non-monetary incentives. The 6-month response rate increased to 98.9% for surveys scheduled within the second year. Overall, 155 of 168 (92.3%) participants completed the 6-month postintervention survey.

Discussion {#s4}
==========

This report describes the methods implemented to recruit and retain African--American women with SLE into the CDSMP, a 6-week, group-based, generic self-management education programme. Within a 2-year period, 168 African--American women with SLE attended the CDSMP, 126 (75%) completed ≥4 weekly classes and 155 (92.3%) responded to the 6-month postintervention survey. We encountered, however, various challenges in meeting the desired study goals, which can be grouped into two major categories: (1) CDSMP coordination to accommodate participants' needs and (2) participant barriers to attending and completing the programme.

CDSMP coordination {#s4-1}
------------------

CDSMP workshops in Atlanta are primarily delivered by organisations that largely target the chronically ill and elderly population and coordinated by the ARC, which is licensed to deliver CDSMP in metro Atlanta.[@R43] Consequently, it was difficult to match the most common workshop locations (senior centres) and schedules (morning days of the week) with our participants' preferences. Strategic solutions included a tight coordination between the study staff and the ARC to deliver conveniently located workshops, including healthcare facilities familiar to our participants. Moreover, afternoon and Saturday CDSMP workshops enabled attendance of those who had medical appointments, full-time jobs or caregiver commitments. We also consented a larger number of participants to reduce the likelihood of workshop cancellation associated with insufficient number of participants.

Participant barriers {#s4-2}
--------------------

SLE poses a substantial toll to African--American women, with multiple negative consequences on their lives. With over 80% of the study population reporting some type of organ damage and 60% being unemployed or disabled, unpredicted health-related and personal-related problems were common threats to CDSMP attendance and completion. The average scores of SLE activity, physical health, mental health and depression suggest that many of these patients may not have had adequate control of the disease and comorbidities. Since these factors lead to poor outcomes and higher healthcare utilisation, our participants frequently faced barriers to attending the 6-week CDSMP classes. Other studies have emphasised that demands from family, work and stressful life events are challenges often faced by minorities, which can limit their engagement in interventional studies.[@R44] More flexible and additional workshops contributed to increased attendance from 45 to 123 participants in the first and second half of the study period.

Other studies among African--Americans have identified mistrust as a major recruitment barrier.[@R46] Since our team has built a long-standing relationship with GOAL participants, mistrust was not perceived as an issue in our study. However, despite the experience of the research team working with African--Americans, some women showed a poor understanding of the objective and structured nature of the CDSMP. Cultural adaptations of the recruitment materials, frequent communication with participants and the implementation of a demonstration session helped women align their expectations with the objectives of the intervention. These measures have been adopted by others as effective strategies to engage African--American in clinical trials and may have contributed to the reduced number of last-minute cancellations and no-shows in our study.[@R47] Other procedures that helped to overcome retention challenges were weekly class reminders, non-monetary rewards and transportation support. The importance of these strategies in increasing trial retention among minority populations has been emphasised in other studies.[@R42]

Our study has limitations. First, we did not conduct a formal qualitative assessment of barriers and potential solutions. However, experienced RCs took notes and provided ongoing insight that served to successfully modify our recruitment and retention procedures. Second, in order to reduce participants' barriers to workshops attendance, we implemented procedures (eg, class reminders, non-monetary compensation) that represent deviations from the real-world CDSMP. Third, to achieve the desired sample size within the study timeline, some of the workshops were attended exclusively by study participants. Interestingly, WELL women who also participated in a qualitative substudy did not raise organic concerns about the diverse composition of the CDSMP groups.[@R11] A deeper assessment is warranted to determine the influence of demographic and disease-related factors on the programme outcomes. Fourth, findings of this study are best generalised to African--American women in the Southeastern USA and not to other racial/ethnic groups and in other regions or countries. Fifth, the lack of RCs might impact participation of patients with SLE in the real-world CDSMP. However, providers and organisations that advocate for patients with lupus can play a key role by referring patients and providing support to the most vulnerable groups. Alternative community-based strategies that might work for this population include internet-based CDSMP, CDSMP delivered by organisations who target minorities with lupus, and video conference for participants who attended first class but have mobility or transportation challenges at the time of other classes.

The strengths of our study include the intentional focus on identifying recruitment and retention challenges, and a proactive and nimble research team able to implement strategies to reduce barriers. We did not consider altering the 6-week programme delivery protocol since this study is designed to evaluate the effects of a widely available community intervention among our high-need minority population, rather than to develop a new intervention. The overall completion rate (75%) in this sample, however, is relatively high considering that lupus is a complex condition with high prevalence of comorbid conditions and symptoms that wax and wane. Although some solutions to reduce barriers to workshop attendance were facilitated by the research grant (eg, reducing transportation costs), many others could be implemented in the community because they were either free (hold classes at convenient locations, hold Saturday classes, overenrol to avoid workshop cancellations) or low cost (reminder calls/texts, token incentives). In addition, the design enabled recruitment of a large number of participants who have been historically under-represented in research, proving to be a feasible option to save time and costs.

In conclusion, by establishing performance standards and conducting constant assessment of progress and barriers, we were able to adjust our strategies to meet the desired recruitment and retention outcomes. A trustful relationship through culturally competent research members, trial information that aligns participants' needs and intervention outcomes, transportation support, and flexibility to consider personal and illness-related demands of participants were fundamental strategies to successfully engage and retain a large cohort of African--American women with SLE into a generic, group-based self-management programme. Should further findings support a benefit of the CDSMP among African--American women with SLE, the feasibility of implementing these strategies in the real world may be considered to facilitate the participation of this minority in the CDSMP.
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